FierceBiotech

Recursion bags $60M for AI-enabled drug discovery push

Recursion Pharmaceuticals has raised $60 million to step up its artificial intelligence-enabled drug discovery activities. The series B equips Recursion to move beyond its initial focus on repurposing ...
BioWorld

Recursion closes on a $121M series C for AI-backed R&D

Some new investors pitched in to Recursion Pharmaceuticals Inc.'s $121 million series C financing, adding to the industry's vision of the importance of AI and machine learning. The round was led by ...
Business Wire

Recursion Raises Additional Funding, Bringing Total Series A to $15.05M for Drug Discovery

SALT LAKE CITY--(BUSINESS WIRE)--Recursion Pharmaceuticals today announced the close of an additional $2.15M in funding, bringing its Series A round to a total of $15.05M for drug discovery at the ...
FierceBiotech

Recursion Pharma nets $239M, plus an AI research contract with Bayer

Recursion Pharmaceuticals has secured $239 million in new venture capital financing, plus a long-term collaboration deal with Bayer to help boost its pipeline in fibrotic diseases of the lung, heart, ...
Wall Street Journal

Recursion Raises $239 Million Series D Round, Strikes Deal With Bayer

Digital drug-discovery startup Recursion Pharmaceuticals Inc. has formed a partnership with Bayer AG that could be worth more than $1 billion and also raised a $239 million venture financing round led ...
Wall Street Journal

Recursion Pharmaceuticals Gathers $13M Series A for Rare Disease Therapies

Recursion Pharmaceuticals LLC has raised $12.9 million in Series A financing on the promise that it can convert drugs idling on pharmaceutical companies’ shelves into therapies for rare diseases. is ...